
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA is focused on developing its lead product candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH), a condition with no currently approved therapies, which positions the company to potentially capture a significant market share. The clinical trial results indicate that lanifibranor is unique in achieving both MASH resolution and fibrosis improvement within 24 weeks, with nearly 42% of participants showing fibrosis improvement compared to only 24% in the placebo group, suggesting a strong therapeutic profile. Additionally, partnership revenues with AbbVie and BI provide financial stability while the potential for lanifibranor to serve as a complementary therapy in combination treatments could accelerate its adoption and enhance prospects for success in the evolving NASH treatment landscape.
Bears say
Inventiva SA reported a significant net loss of €175.9 million, translating to a loss of €1.62 per share, which raises concerns about its financial stability and future operations. The company is facing considerable risks, including potential clinical trial failures, delays in development timelines, and challenges in accessing favorable equity capital, all of which could hinder its ability to execute planned operations. Furthermore, the competitive landscape in NASH treatment is problematic, as currently approved therapies have shown modest efficacy in key areas such as liver histology, raising doubts about the market potential for Inventiva's lead candidate, lanifibranor.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares